ADDED
iii PART I Unless otherwise indicated or the context otherwise requires, all references in this prospectus to we, us, our, Lunai or the Company are to Lunai Bioworks Inc.
operates through three subsidiaries, Renovaro Biosciences, Renovaro Cube and BioSymetrics.
and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025.
Renovaro Biosciences Overview Renovaro Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers.
This transition to focus more strongly on molecular diagnostics and oncology allows us to better align with market trends and streamline our efforts to indication areas where we see strong market fit.
Resources As of the year ended June 30, 2025, Renovaro Cube intends to hire additional staff to increase the speed and velocity of its organization, including the development of the AI platform and the opportunities to deploy the AI platform for research perspective and ultimately for clinical practice and into clinical trials.
10 Business Overview (BioSymetrics) BioSymetrics is a biomedical artificial intelligence company focused on integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.
BioSymetrics has developed proprietary machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights.
These insights are designed to support pharmaceutical research, early disease detection, and personalized treatment strategies.
BioSymetrics collaborates with pharmaceutical companies, healthcare providers, and academic institutions to co-develop analytical tools and translational research programs.
REMOVED
operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube.
Renovaro Biosciences Overview Renovaro Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections.
Gene Therapy Renovaro Biosciences may also seek to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation of the patient s immune system.
Upon injecting into the patients, these genetically engineered allogeneic cells have little to no risk of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the host immune system.
Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient s immune system therefore will have a very short survival time.
Infectious Diseases: RENB-HV12: Genetically Modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of HIV; A Chronic Infectious Disease The oncology therapeutic vaccine technology could potentially be adapted to target infectious disease antigens and be a viable therapeutic approach in difficult to treat chronic infectious diseases.
As described above, the engineered allogenic dendritic cell drug substance is thought to be able to be loaded with various cancer antigens for specific solid tumors but could or may be loaded with infectious disease antigens to elicit a more robust immune response to viruses and other difficult to treat infections.
Resources Renovaro Cube intends to hire additional staff to increase the speed and velocity of its organization, including the development of the AI platform and the opportunities to deploy the AI platform for research perspective and ultimately for clinical practice and into clinical trials.
12 Differential diagnosis is important for several reasons: 1.
20 Employees As of June 30, 2024, we had 25 full-time employees.